Skip to main content
Terug
MANE logo

Veradermics, Incorporated

Datakwaliteit: 100%
Overbought
MANE
NYSE Healthcare Biotechnology
€ 65,56
▲ € 2,07 (3,26%)
Marktkapitalisatie: 2,30B
Dagbereik
€ 62,28 € 66,54
52-Weeksbereik
€ 32,00 € 66,54
Volume
428.108
50D / 200D Gem.
€ 47,48 / € 47,48
Vorige Slotkoers
€ 63,49

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E -86,8 0,2
P/B 42,1 3,0
ROE % -76,5 3,6
Net Margin % 3,8
Rev Growth 5Y % 9,7
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 75,00 +14.4%
Forward WPA
-€ 2,57
Omzet Sch.
0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2028 -€ 3,10
-€ 5,10 – -€ 1,60
48,70M 3
FY2027 -€ 2,59
-€ 3,12 – -€ 2,00
10,39M 3
FY2026 -€ 2,57
-€ 2,79 – -€ 2,35
0,0 2

Earnings Surprises

Last 1 quarter
Quarter Est. EPS Actual EPS Surprise
2026-02-25 -€ 0,92 -€ 1,63 -76,5%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -23,69M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-76,46%
ROIC-36,74%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,00
Current Ratio11,77
Interest Coverage-45,77

Waardering

P/E Ratio
-86,82
Forward P/EN/A
P/B Ratio42,07
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -26,49M
ROE -76,46% ROA -44,61%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -23,69M
ROIC -36,74% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 11,77
Interest Coverage -45,77
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -86,82 Forward P/E N/A
P/B Ratio 42,07 P/S Ratio N/A
PEG Ratio -4,04 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1,03%
Market Cap 2,30B Enterprise Value 2,25B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023
Revenue 0,0 0,0
Net Income -26,49M -16,49M
EPS (Diluted) -0,14 -0,08
Gross Profit 0,0 0,0
Operating Income -26,78M -17,32M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023
Total Assets 59,38M 18,46M
Total Liabilities 4,72M 3,84M
Shareholders' Equity 54,67M 14,62M
Total Debt 0,0 786.000,0
Cash & Equivalents 53,08M 16,30M
Current Assets 55,54M 17,56M
Current Liabilities 4,72M 3,05M